McKesson (NYSE:MCK) was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a note issued to investors on Monday, February 4th.
A number of other equities research analysts have also commented on MCK. Zacks Investment Research upgraded McKesson from a “sell” rating to a “hold” rating in a research report on Wednesday, January 9th. Barclays decreased their price target on McKesson from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research report on Friday, October 26th. Morgan Stanley decreased their price objective on McKesson from $142.00 to $130.00 and set an “equal weight” rating on the stock in a research report on Monday, December 3rd. Deutsche Bank upgraded McKesson from a “sell” rating to a “hold” rating and set a $175.00 price objective on the stock in a research report on Friday, January 25th. Finally, UBS Group assumed coverage on McKesson in a research report on Thursday, January 17th. They issued a “neutral” rating and a $134.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $137.99.
Shares of MCK stock traded down $2.63 during trading hours on Monday, hitting $124.53. The company had a trading volume of 1,549,119 shares, compared to its average volume of 1,566,529. McKesson has a 12 month low of $106.11 and a 12 month high of $160.87. The firm has a market cap of $25.22 billion, a P/E ratio of 9.87, a P/E/G ratio of 1.37 and a beta of 1.25. The company has a current ratio of 1.02, a quick ratio of 0.57 and a debt-to-equity ratio of 0.81.
McKesson (NYSE:MCK) last released its quarterly earnings data on Thursday, January 31st. The company reported $3.40 earnings per share for the quarter, beating the consensus estimate of $3.18 by $0.22. The company had revenue of $56.21 billion for the quarter, compared to analyst estimates of $55.27 billion. McKesson had a positive return on equity of 27.83% and a negative net margin of 0.15%. During the same period in the prior year, the company posted $3.41 EPS. Sell-side analysts forecast that McKesson will post 13.55 EPS for the current year.
In other news, EVP Lori A. Schechter sold 7,700 shares of the stock in a transaction on Wednesday, January 16th. The stock was sold at an average price of $122.96, for a total value of $946,792.00. Following the transaction, the executive vice president now owns 10,000 shares of the company’s stock, valued at approximately $1,229,600. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.87% of the company’s stock.
A number of institutional investors have recently modified their holdings of MCK. Atria Investments LLC raised its stake in McKesson by 23.5% during the 3rd quarter. Atria Investments LLC now owns 10,270 shares of the company’s stock worth $1,362,000 after buying an additional 1,956 shares during the period. We Are One Seven LLC bought a new position in shares of McKesson in the 3rd quarter valued at about $506,000. State of Alaska Department of Revenue grew its holdings in shares of McKesson by 2.0% in the 3rd quarter. State of Alaska Department of Revenue now owns 31,454 shares of the company’s stock valued at $4,171,000 after acquiring an additional 608 shares in the last quarter. Trust Department MB Financial Bank N A grew its holdings in shares of McKesson by 1.0% in the 3rd quarter. Trust Department MB Financial Bank N A now owns 41,256 shares of the company’s stock valued at $5,473,000 after acquiring an additional 428 shares in the last quarter. Finally, Midas Management Corp grew its holdings in shares of McKesson by 78.6% in the 3rd quarter. Midas Management Corp now owns 11,365 shares of the company’s stock valued at $1,507,000 after acquiring an additional 5,000 shares in the last quarter. 87.31% of the stock is currently owned by institutional investors and hedge funds.
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.